Cytosorbents (CTSO) Net Equity Issued and Repurchased (2012 - 2024)

Cytosorbents (CTSO) posted Net Equity Issued and Repurchased of -$238.0 for Q2 2024, down 100.45% on a QoQ basis from $53238.0 in Q1 2024.

Cytosorbents (CTSO) Net Equity Issued and Repurchased (2012 - 2024) Analysis & Trends

Cytosorbents' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at -$238.0 for Q2 2024.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$238.0 in Q2 2024, while the trailing twelve-month figure through Sep 2024 was $694733.0 (changed N/A YoY) and the FY2023 annual result came in at $4.5 million, changed N/A from the prior year.
Net Equity Issued and Repurchased was -$238.0 for Q2 2024 at Cytosorbents, down from $53238.0 in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $641733.0 in Q1 2023 and bottomed at -$238.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	97.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	12.70 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Cytosorbents	22.58 Mn	17.78 Mn	6.13 Mn	-

Download Data